Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Показания к реваскуляризации миокарда (Российский cогласительный документ)

ЛИТЕРАТУРА

  1. Pocock S. J., Henderson R. A., Rickards A. F. et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery // Lancet. – 1995. – Vol. 346. – P. 1184–1189.
  2. Rodes-Cabau J., Deblois J., Bertrand O. F.et al. Nonrandomized comparison of coronary artery bypass surgery and percutaneous coronary intervention for the treatment of unprotected left main coronary artery disease in octogenarians // Circulation. – 2008. – Vol. 118. – P. 2374–2381.
  3. Min S. Y., Park D. W., Yun S. C. et al. Major predictors of long-term clinical outcomes after coronary revascularization in patients with unprotected left main coronary disease: analysis from the MAIN-COMPARE study // Circ. Cardiovasc. Interv. – 2010. – Vol. 3. – P. 127–133.
  4. Serruys P. W., Morice M. C., Kappetein A. P. et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease // N. Engl. J. Med. – 2009. – Vol. 360. – P. 961–972.
  5. Peterson E. D., Dai D., DeLong E. R. et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry // J. Am. Coll. Cardiol. – 2010. – Vol. 55. – P. 1923–1932.
  6. Nashef S. A., Roques F., Michel P. et al. European system for cardiac operative risk evaluation (EuroSCORE) // Eur. J. Cardiothorac. Surg. – 1999. – Vol. 16. – P. 9–13.
  7. Singh M., Rihal C. S., Lennon R. J. et al. Bedside estimation of risk from percutaneous coronary intervention: the new Mayo Clinic risk scores // Mayo Clin. Proc. – 2007. – Vol. 82. – P. 701–708.
  8. Singh M., Gersh B. J., Li S. et al. Mayo Clinic risk score for percutaneous coronary intervention predicts in-hospital mortality in patients undergoing coronary artery bypass graft surgery // Circulation. – 2008. – Vol. 117. – P. 356–362.
  9. Parsonnet V., Dean D., Bernstein A. D. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease // Circulation. – 1989. – Vol. 79. – P. I3–I12.
  10. Shahian D. M., O’Brien S. M., Filardo G. et al. The Society of Thoracic Surgeons. 2008 cardiac surgery risk models: part 1–coronary artery bypass grafting surgery // Ann. Thorac. Surg. – 2009. – Vol. 88. – P. S2–S22.
  11. Ranucci M., Castelvecchio S., Menicanti L. et al. Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony // Circulation. – 2009. – Vol. 119. – P. 3053–3061.
  12. Fox K., Garcia M. A., Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology // Eur. Heart J. – 2006. – Vol. 27. – P. 1341–1381.
  13. Davies R. F., Goldberg A. D., Forman S. et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization // Circulation. – 1997. – Vol. 95. – P. 2037–2043.
  14. Shaw L. J., Berman D. S., Maron D. J. et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy // Circulation. – 2008. – Vol. 117. – P. 1283–1291.143
  15. Pijls N. H., van Schaardenburgh P., Manoharan G. et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study // J. Am. Coll. Cardiol. – 2007. – Vol. 49. – P. 2105–2111.
  16. Allman K. C., Shaw L. J., Hachamovitch R., Udelson J. E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis //J. Am. Coll. Cardiol. – 2002. – Vol. 39. – P. 1151–1158.
  17. Beanlands R. S., Nichol G., Huszti E. et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2) // J. Am. Coll. Cardiol. – 2007. – Vol. 50. – P. 2002–2012.
  18. Bluemke D. A., Achenbach S., Budoff M. et al. Noninvasive coronary artery imaging: magnetic resonance angiography and multidetector computed tomography angiography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and intervention of the Council on Cardiovascular Radiology and Intervention, and the Councils on Clinical Cardiology and Cardiovascular Disease in the Young // Circulation. – 2008. – Vol. 118. – P. 586–606.
  19. Schroeder S., Achenbach S., Bengel F. et al. Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology // Eur. Heart J. – 2008. – Vol. 29. – P. 531–556.
  20. Meijboom W. B., Meijs M. F., Schuijf J. D. et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study // J. Am. Coll. Cardiol. – 2008. – Vol. 52. – P. 2135–2144.
  21. Miller J. M., Rochitte C. E., Dewey M. et al. Diagnostic performance of coronary angiography by 64-row CT // N. Engl. J. Med. – 2008. – Vol. 359. – P. 2324–2336.
  22. Sarno G., Decraemer I., Vanhoenacker P. K. et al. On the inappropriateness of noninvasive multidetector computed tomography coronary angiography to trigger coronary revascularization: a comparison with invasive angiography // JACC Cardiovasc. Interv. – 2009. – Vol. 2. – P. 550–557.
  23. Giri S., Shaw L. J., Murthy D. R. et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease // Circulation. – 2002. – Vol. 105. – P. 32–40.
  24. Schuijf J. D., Wijns W., Jukema J. W. et al. A comparative regional analysis of coronary atherosclerosis and calcium score on multislice CT versus myocardial perfusion on SPECT // J. Nucl. Med. – 2006. – Vol. 47. – P. 1749–1755.
  25. Nandalur K. R., Dwamena B. A., Choudhri A. F. et al. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis // J. Am. Coll. Cardiol. – 2007. – Vol. 50. – P. 1343–1353.
  26. Bateman T. M., Heller G. V., McGhie A. I. et al. Diagnostic accuracy of rest/ stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECGgated Tc-99m sestamibi SPECT // J. Nucl. Cardiol. – 2006. – Vol. 13. – P. 24–33.
  27. Botman K. J., Pijls N. H., Bech J. W. et al. Percutaneous coronary intervention or bypass surgery in multivessel disease? A tailored approach based on coronary pressure measurement // Catheter. Cardiovasc. Interv. – 2004. – Vol. 63. – P. 184–191.
  28. Tonino P. A., de Bruyne B., Pijls N. H. et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention // N. Engl. J. Med. – 2009. – Vol. 360. – P. 213–224.
  29. Hlatky M. A., Boothroyd D. B., Bravata D. M. et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials // Lancet. – 2009. – Vol. 373. – P. 1190–1197.
  30. Jeremias A., Kaul S., Rosengart T. K. et al. The impact of revascularization on mortality in patients with nonacute coronary artery disease // Am. J. Med. – 2009. – Vol. 122. – P. 152–161.
  31. Yusuf S., Zucker D., Peduzzi P. et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration // Lancet. – 1994. – Vol. 344. – P. 563–570.
  32. Brener S. J., Lytle B. W., Casserly I. P. et al. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features // Circulation. – 2004. – Vol. 109. – P. 2290–2295.
  33. Hannan E. L., Racz M. J., Walford G. et al. Long-term outcomes of coronaryartery bypass grafting versus stent implantation // N. Engl. J. Med. – 2005. – Vol. 352. – P. 2174–2183.
  34. Hannan E. L., Wu C., Walford G. et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease // N. Engl. J. Med. – 2008. – Vol. 358. – P. 331–341.
  35. Malenka D. J., Leavitt B. J., Hearne M. J. et al. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England // Circulation. – 2005. – Vol. 112. – P. I371–I376.
  36. Smith P. K., Califf R. M., Tuttle R. H. et al. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit // Ann. Thorac. Surg. – 2006. – Vol. 82. – P. 1420–1428.
  37. Dzavik V., Ghali W. A., Norris C. et al. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators // Am. Heart J. – 2001. – Vol. 142. – P. 119–126.
  38. Hachamovitch R., Hayes S. W., Friedman J. D. et al. Comparison of the shortterm survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography // Circulation. – 2003. – Vol. 107. – P. 2900–2907.
  39. Bucher H. C., Hengstler P., Schindler C., Guyatt G. H. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials // BMJ. – 2000. – Vol. 321. – P. 73–77.
  40. Katritsis D. G., Ioannidis J. P. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis // Circulation. – 2005. – Vol. 111. – P. 2906–2912.
  41. Schomig A., Mehilli J., de Waha A. et al. A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease // J. Am. Coll. Cardiol. – 2008. – Vol. 52. – P. 894–904.
  42. Trikalinos T. A., Alsheikh-Ali A. A., Tatsioni A. et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis // Lancet. – 2009. – Vol. 373. – P. 911–918.
  43. Boden W. E., O’Rourke R. A., Teo K. K. et al. Optimal medical therapy with or without PCI for stable coronary disease // N. Engl. J. Med. – 2007. – Vol. 356. – P. 1503–1516.
  44. Brophy J. M., Belisle P., Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis // Ann. Intern. Med. – 2003. – Vol. 138. – P. 777–786.
  45. Stettler C., Wandel S., Allemann S. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis // Lancet. – 2007. – Vol. 370. – P. 937–948.
  46. Kirtane A. J., Gupta A., Iyengar S. et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies // Circulation. – 2009. – Vol. 119. – P. 3198–3206.
  47. Loop F. D., Lytle B. W., Cosgrove D. M. et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events // N. Engl. J. Med. – 1986. – Vol. 314. – P. 1–6.
  48. Lytle B. W., Blackstone E. H., Sabik J. F. et al. The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years // Ann. Thorac. Surg. – 2004. – Vol. 78. – P. 2005–2012.
  49. Taggart D. P., D’Amico R., Altman D. G. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries // Lancet. – 2001. – Vol. 358. – P. 870–875.
  50. Aziz O., Rao C., Panesar S. S. et al. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery // BMJ. – 2007. – Vol. 334. – P. 617.
  51. Kapoor J. R., Gienger A. L., Ardehali R. et al. Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery // JACC Cardiovasc. Interv. – 2008. – Vol. 1. – P. 483–491.
  52. Taggart D. P., Thomas B. Ferguson Lecture. Coronary artery bypass grafting is still the best treatment for multivessel and left main disease, but patients need to know // Ann. Thorac. Surg. – 2006. – Vol. 82. – P. 1966–1975.
  53. Hueb W., Lopes N. H., Gersh B. J. et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease // Circulation. – 2007. – Vol. 115. – P. 1082–1089.
  54. Caracciolo E. A., Davis K. B., Sopko G. et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience // Circulation. – 1995. – Vol. 91. – P. 2335–2344.
  55. Silber S., Albertsson P., Aviles F. F. et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology // Eur. Heart J. – 2005. – Vol. 26. – P. 804–847.
  56. Naik H., White A. J., Chakravarty T. et al. A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis // JACC Cardiovasc. Interv. – 2009. – Vol. 2. – P. 739–747.
  57. Park D. W., Seung K. B., Kim Y. H. et al. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry // J. Am. Coll. Cardiol. – 2010. – Vol. 56. – P. 117–124.
  58. Mehta S. R., Cannon C. P., Fox K. A. et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials // JAMA. – 2005. – Vol. 293. – P. 2908–2917.
  59. Fox K. A., Clayton T. C., Damman P. et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data // J. Am. Coll. Cardiol. – 2010. – Vol. 55. – P. 2435–2445.
  60. Bassand J. P., Hamm C. W., Ardissino D. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes // Eur. Heart J. – 2007. – Vol. 28. – P. 1598–1660.
  61. Yan A. T., Yan R. T., Tan M. et al. In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score // Am. J. Cardiol. – 2005. – Vol. 96. – P. 913–916.
  62. Lagerqvist B., Husted S., Kontny F. et al. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study // Lancet. – 2006. – Vol. 368. – P. 998–1004.
  63. Damman P., Hirsch A., Windhausen F. et al. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome // J. Am. Coll. Cardiol. – 2010. – Vol. 55. – P. 858–864.
  64. Fox K. A., Poole-Wilson P., Clayton T. C. et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial // Lancet. – 2005. – Vol. 366. – P. 914–920.
  65. Giugliano R. P., White J. A., Bode C. et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes // N. Engl. J. Med. – 2009. – Vol. 360. – P. 2176–2190.
  66. Mehta S. R., Granger C. B., Boden W. E. et al. Early versus delayed invasive intervention in acute coronary syndromes // N. Engl. J. Med. – 2009. – Vol. 360. – P. 2165–2175.
  67. O’Donoghue M., Boden W. E., Braunwald E. et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and nonST-segment elevation myocardial infarction: a meta-analysis // JAMA. – 2008. – Vol. 300. – P. 71–80.
  68. Bavry A. A., Kumbhani D. J., Rassi A. N. et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials // J. Am. Coll. Cardiol. – 2006. – Vol. 48. – P. 1319–1325.
  69. Cannon C. P., Weintraub W. S., Demopoulos L. A. et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban // N. Engl. J. Med. – 2001. – Vol. 344. – P. 1879–1887.
  70. Wallentin L., Lagerqvist B., Husted S. et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease // Lancet. – 2000. – Vol. 356. – P. 9–16.
  71. Neumann F. J., Kastrati A., Pogatsa-Murray G. et al. Evaluation of prolonged antithrombotic pretreatment («cooling-off’» strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial // JAMA. – 2003. – Vol. 290. – P. 1593–1599.
  72. Montalescot G., Cayla G., Collet J. P. et al. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial // JAMA. – 2009. – Vol. 302. – P. 947–954.
  73. Keeley E. C., Boura J. A., Grines C. L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials // Lancet. – 2003. – Vol. 361. – P. 13–20.
  74. Kalla K., Christ G., Karnik R. et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry) // Circulation. – 2006. – Vol. 113. – P. 2398–2405.
  75. Zahn R., Schiele R., Schneider S. et al. Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis. Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Registry and the Myocardial Infarction Registry (MIR) // J. Am. Coll. Cardiol. – 2000. – Vol. 36. – P. 2064–2071.
  76. Smith S. C. Jr, Feldman T. E., Hirshfeld J. W. Jr et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention) // Circulation. – 2006. – Vol. 113. – P. e166–e286.
  77. Cantor W. J., Fitchett D., Borgundvaag B. et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction // N. Engl. J. Med. – 2009. – Vol. 360. – P. 2705–2718.
  78. Di Mario C., Dudek D., Piscione F. et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESSin-AMI): an open, prospective, randomised, multicentre trial // Lancet. – 2008. – Vol. 371. – P. 559–568.
  79. Fernandez-Aviles F., Alonso J. J., Castro-Beiras A. et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA1): a randomised controlled trial // Lancet. – 2004. – Vol. 364. – P. 1045–1053.
  80. Gershlick A. H., Stephens-Lloyd A., Hughes S. et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction // N. Engl. J. Med. – 2005. – Vol. 353. – P. 2758–2768.
  81. Bonnefoy E., Steg P. G., Boutitie F. et al. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up // Eur. Heart J. – 2009. – Vol. 30. – P. 1598–1606.
  82. Widimsky P., Wijns W., Fajadet J. et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries // Eur. Heart J. – 2010. – Vol. 31. – P. 943–957.
  83. Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients // Eur. Heart J. – 2006. – Vol. 27. – P. 779–788.
  84. Nallamothu B., Fox K. A., Kennelly B. M. et al. Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events // Heart. – 2007. – Vol. 93. – P. 1552–1555.
  85. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT4 PCI): randomised trial // Lancet. – 2006. – Vol. 367. – P. 569–578.
  86. Ellis S. G., Tendera M., de Belder M. A. et al. Facilitated PCI in patients with ST-elevation myocardial infarction // N. Engl. J. Med. – 2008. – Vol. 358. – P. 2205–2217.
  87. Wijeysundera H. C., Vijayaraghavan R., Nallamothu B. K. et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials // J. Am. Coll. Cardiol. – 2007. – Vol. 49. – P. 422–430.
  88. Busk M., Kaltoft A., Nielsen S. S. et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for,12 h vs. 12–72 h // Eur. Heart J. – 2009. – Vol. 30. – P. 1322–1330.
  89. Schomig A., Mehilli J., Antoniucci D. et al. Mechanical ESC/EACTS Guidelines 2549 reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial // JAMA. – 2005. – Vol. 293. – P. 2865–2872.
  90. Hochman J. S., Lamas G. A., Buller C. E. et al. Coronary intervention for persistent occlusion after myocardial infarction // N. Engl. J. Med. – 2006. – Vol. 355. – P. 2395–2407.
  91. Steg P. G., Thuaire C., Himbert D. et al. DECOPI (desobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction // Eur. Heart J. – 2004. – Vol. 25. – P. 2187–2194.
  92. Weiss E. S., Chang D. D., Joyce D. L. et al. Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data // J. Thorac. Cardiovasc. Surg. – 2008. – Vol. 135. – P. 503–511.
  93. Dickstein K., Cohen-Solal A., Filippatos G. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) // Eur. Heart J. – 2008. – Vol. 29. – P. 2388–2442.
  94. Van De Werf F., Bax J., Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology // Eur. Heart J. – 2008. – Vol. 29. – P. 2909–2945.
  95. Hochman J. S., Sleeper L. A., Webb J. G. et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction // JAMA. – 2006. – Vol. 295. – P. 2511–2515.
  96. Sjauw K. D., Engstrom A. E., Vis M. M. et al. A systematic review and metaanalysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? // Eur. Heart J. – 2009. – Vol. 30. – P. 459–468.
  97. Thiele H., Sick P., Boudriot E. et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock // Eur. Heart J. – 2005. – Vol. 26. – P. 1276–1283.
  98. Vanzetto G., Akret C., Bach V. et al. Percutaneous extracorporeal life support in acute severe hemodynamic collapses: single centre experience in 100 consecutive patients // Can. J. Cardiol. – 2009. – Vol. 25. – P. e179–e186.
  99. Dang N. C., Topkara V. K., Leacche M. et al. Left ventricular assist device implantation after acute anterior wall myocardial infarction and cardiogenic shock: a two-center study // J. Thorac. Cardiovasc. Surg. – 2005. – Vol. 130. – P. 693–698.
  100. Seyfarth M., Sibbing D., Bauer I. et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction // J. Am. Coll. Cardiol. – 2008. – Vol. 52. – P. 1584–1588.
  101. Cheng J. M., den Uil C. A., Hoeks S. E. et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials // Eur. Heart J. – 2009. – Vol. 30. – P. 2102–2108.
  102. Fosbol E. L., Thune J. J., Kelbaek H. et al. Long-term outcome of primary angioplasty compared with fibrinolysis across age groups: a Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2) substudy // Am. Heart J. – 2008. – Vol. 156. – P. 391–396.
  103. Knot J., Widimsky P., Wijns W. et al. How to set up an effective national primary angioplasty network: lessons learned from five European countries // EuroIntervention. – 2009. – Vol. 5. – P. 299, 301–309.
  104. Widimsky P., Bilkova D., Penicka M. et al. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years’ follow-up of the PRAGUE-2 Trial // Eur. Heart J. – 2007. – Vol. 28. – P. 679–684.
  105. Vakili B. A., Kaplan R., Brown D. L. Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state // Circulation. – 2001. – Vol. 104. – P. 2171–2176.
  106. Di Mario C., Mara S., Flavio A. et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study // Int. J. Cardiovasc. Intervent. – 2004. – Vol. 6. – P. 128–133.
  107. Ijsselmuiden A. J., Ezechiels J., Westendorp I. C. et al. Complete versus culprit vessel percutaneous coronary intervention in multivessel disease: a randomized comparison // Am. Heart J. – 2004. – Vol. 148. – P. 467–474.
  108. Bradley E. H., Herrin J., Wang Y. et al. Strategies for reducing the door-toballoon time in acute myocardial infarction // N. Engl. J. Med. – 2006. – Vol. 355. – P. 2308–2320.
  109. Pinto D. S., Kirtane A. J., Nallamothu B. K. et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy // Circulation. – 2006. – Vol. 114. – P. 2019–2025.
  110. Ryden L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) // Eur. Heart J. – 2007. – Vol. 28. – P. 88–136.
  111. Frye R. L., August P., Brooks M. M. et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease // N. Engl. J. Med. – 2009. – Vol. 360. – P. 2503–2515.
  112. Timmer J. R., Ottervanger J. P., de Boer M. J. et al. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial // Arch. Intern. Med. – 2007. – Vol. 167. – P. 1353–1359.
  113. Sedlis S. P., Morrison D. A., Lorin J. D. et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry // J. Am. Coll. Cardiol. – 2002. – Vol. 40. – P. 1555–1566.
  114. Kapur A., Hall R. J., Malik I. S. et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial // J. Am. Coll. Cardiol. – 2010. – Vol. 55. – P. 432–440.
  115. Stettler C., Allemann S., Wandel S. et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis // BMJ. – 2008. – Vol. 337. – P. a1331.
  116. Locker C., Mohr R., Lev-Ran O. et al. Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients // Ann. Thorac. Surg. – 2004. – Vol. 78. – P. 471–475.
  117. Mellbin L. G., Malmberg K., Norhammar A. et al. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial // Eur. Heart J. – 2008. – Vol. 29. – P. 166–176.
  118. Cheung N. W., Wong V. W., McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction // Diabetes. Care. – 2006. – Vol. 29. – P. 765–770.
  119. Mehta S. R., Yusuf S., Diaz R. et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial // JAMA. – 2005. – Vol. 293. – P. 437–446.
  120. Lazar H. L., Chipkin S. R., Fitzgerald C. A. et al. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events // Circulation. – 2004. – Vol. 109. – P. 1497–1502.
  121. Quinn D. W., Pagano D., Bonser R. S. et al. Improved myocardial protection during coronary artery surgery with glucose-insulin-potassium: a randomized controlled trial // J. Thorac. Cardiovasc. Surg. – 2006. – Vol. 131. – P. 34–42.
  122. Finfer S., Chittock D. R., Su S. Y. et al. Intensive versus conventional glucose control in critically ill patients // N. Engl. J. Med. – 2009. – Vol. 360. – P. 1283–1297.
  123. Poldermans D., Bax J. J., Boersma E. et al. Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in noncardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA) // Eur. Heart J. – 2009. – Vol. 30. – P. 2769–2812.
  124. Laskey W. K., Jenkins C., Selzer F. et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention // J. Am. Coll. Cardiol. – 2007. – Vol. 50. – P. 584–590.
  125. Adabag A. S., Ishani A., Bloomfield H. E. et al. Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials // Eur. Heart J. – 2009. – Vol. 30. – P. 1910–1917.
  126. Kolh P. Renal insufficiency after cardiac surgery: a challenging clinical problem // Eur. Heart J. – 2009. – Vol. 30. – P. 1824–1827.
  127. Brar S. S., Shen A. Y., Jorgensen M. B. et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial // JAMA. – 2008. – Vol. 300. – P. 1038–1046.
  128. Briguori C., Airoldi F., D’Andrea D. et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies // Circulation. – 2007. – Vol. 115. – P. 1211–1217.
  129. Marenzi G., Assanelli E., Marana I. et al. N-acetylcysteine and contrastinduced nephropathy in primary angioplasty // N. Engl. J. Med. – 2006. – Vol. 354. – P. 2773–2782.
  130. Merten G. J., Burgess W. P., Gray L. V. et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial // JAMA. – 2004. – Vol. 291. – P. 2328–2334.
  131. Aspelin P., Aubry P., Fransson S. G. et al. Nephrotoxic effects in high-risk patients undergoing angiography // N. Engl. J. Med. – 2003. – Vol. 348. – P. 491–499.
  132. Jo S. H., Youn T. J., Koo B. K. et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial // J. Am. Coll. Cardiol. – 2006. – Vol. 48. – P. 924–930.
  133. Solomon R. J., Natarajan M. K., Doucet S. et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrastinduced nephropathy in patients with chronic kidney disease // Circulation. – 2007. – Vol. 115. – P. 3189–3196.
  134. Marenzi G., Marana I., Lauri G. et al. The prevention of radiocontrast-agentinduced nephropathy by hemofiltration // N. Engl. J. Med. – 2003. – Vol. 349. – P. 1333–1340.
  135. Marenzi G., Lauri G., Campodonico J. et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients // Am. J. Med. – 2006. – Vol. 119. – P. 155–162.
  136. Vogt B., Ferrari P., Schoђnholzer C. et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful // Am. J. Med. – 2001. – Vol. 111. – P. 692–698.
  137. Herzog C. A., Ma J. Z., Collins A. J. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes // Circulation. – 2002. – Vol. 106. – P. 2207–2211.
  138. Ix J. H., Mercado N., Shlipak M. G. et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS) // Am. Heart J. – 2005. – Vol. 149. – P. 512–519.
  139. Szczech L. A., Reddan D. N., Owen W. F. et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency // Kidney. Int. – 2001. – Vol. 60. – P. 292–299.
  140. Sajja L. R., Mannam G., Chakravarthi R. M. et al. Coronary artery bypass grafting with or without cardiopulmonary bypass in patients with preoperative non-dialysis dependent renal insufficiency: a randomized study // J. Thorac. Cardiovasc. Surg. – 2007. – Vol. 133. – P. 378–388.
  141. Vahanian A., Baumgartner H., Bax J. et al. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology // Eur. Heart J. – 2007. – Vol. 28. – P. 230–268.
  142. Bonow R. O., Carabello B. A., Chatterjee K. et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons // J. Am. Coll. Cardiol. – 2006. – Vol. 48. – P. e1–148.
  143. Byrne J. G., Leacche M., Vaughan D. E., Zhao D. X. Hybrid cardiovascular procedures // JACC Cardiovasc. Interv. – 2008. – Vol. 1. – P. 459–468.
  144. Vahanian A., Alfieri O., Al-Attar N. et al. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI) // Eur. Heart J. – 2008. – Vol. 29. – P. 1463–1470.
  145. Chaturvedi S., Bruno A., Feasby T. et al. Carotid endarterectomy–an evidencebased review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology // Neurology. – 2005. – Vol. 65. – P. 794–801.
  146. Ederle J., Featherstone R. L., Brown M. M. Randomized controlled trials comparing endarterectomy and endovascular treatment for carotid artery stenosis: a Cochrane systematic review // Stroke. – 2009. – Vol. 40. – P. 1373–1380.
  147. Ederle J., Dobson J., Featherstone R. L. et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial // Lancet. – 2010. – Vol. 375. – P. 985–997.
  148. Bonati L. H., Jongen L. M., Haller S. et al. New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS) // Lancet. Neurol. 2010. – Vol. 9. – P. 353–362.
  149. Brott T. G., Hobson R. W., Howard G. et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis // N. Engl. J. Med. – 2010. – Vol. 363. – P. 11–23.
  150. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. – 2002. – Vol. 324. – P. 71–86.
  151. Sacco R. L., Adams R., Albers G. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline // Circulation. – 2006. – Vol. 113. – P. e409–e449.
  152. Brilakis E. S., Hernandez A. F., Dai D. et al. Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program // Circulation. – 2009. – Vol. 120. – P. 560–567.
  153. McFalls E. O., Ward H. B., Moritz T. E. et al. Coronary-artery revascularization before elective major vascular surgery // N. Engl. J. Med. – 2004. – Vol. 351. – P. 2795–2804.
  154. Poldermans D., Schouten O., Vidakovic R. et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study // J. Am. Coll. Cardiol. – 2007. – Vol. 49. – P. 1763–1769.
  155. Monaco M., Stassano P., Di Tommaso L. et al. Systematic strategy of prophylactic coronary angiography improves long-term outcome after major vascular surgery in mediumto high-risk patients: a prospective, randomized study // J. Am. Coll. Cardiol. – 2009. – Vol. 54. – P. 989–996.
  156. Bax L., Woittiez A. J., Kouwenberg H. J. et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial // Ann. Intern. Med. – 2009. – Vol. 150. – P. 840–841.
  157. Leesar M. A., Varma J., Shapira A. et al. Prediction of hypertension improvement after stenting of renal artery stenosis: comparative accuracy of translesional pressure gradients, intravascular ultrasound, and angiography // J. Am. Coll. Cardiol. – 2009. – Vol. 53. – P. 2363–2371.
  158. Eagle K. A., Guyton R. A., Davidoff R. et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery) // Circulation. – 2004. – Vol. 110. – P. 1168–1176.
  159. Jones R. H., Velazquez E. J., Michler R. E. et al. Coronary bypass surgery with or without surgical ventricular reconstruction // N. Engl. J. Med. – 2009. – Vol. 360. – P. 1705–1717.
  160. Di Donato M., Castelvecchio S., Menicanti L. End-systolic volume following surgical ventricular reconstruction impacts survival in patients with ischaemic dilated cardiomyopathy // Eur. J. Heart Fail. – 2010. – Vol. 12. – P. 375–381.
  161. Zhao D. X., Leacche M., Balaguer J. M. et al. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/ operating room // J. Am. Coll. Cardiol. – 2009. – Vol. 53. – P. 232–241.
  162. Tatoulis J., Buxton B. F., Fuller J. A. Patencies of 2127 arterial to coronary conduits over 15 years // Ann. Thorac. Surg. – 2004. – Vol. 77. – P. 93–101.
  163. Desai N. D., Cohen E. A., Naylor C. D., Fremes S. E. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts // N. Engl. J. Med. – 2004. – Vol. 351. – P. 2302–2309.
  164. Patel M. R., Dehmer G. J., Hirshfeld J. W. et al. ACCF/SCAI/STS/AATS/AHA/ ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography // J. Am. Coll. Cardiol. – 2009. – Vol. 53. – P. 530–553.
  165. Sabik J. F. III, Blackstone E. H., Houghtaling P. L. et al. Is reoperation still a risk factor in coronary artery bypass surgery? // Ann. Thorac. Surg. – 2005. – Vol. 80. – P. 1719–1727.
  166. Yau T. M., Borger M. A., Weisel R. D., Ivanov J. The changing pattern of reoperative coronary surgery: trends in 1230 consecutive reoperations // J. Thorac. Cardiovasc. Surg. – 2000. – Vol. 120. – P. 156–163.
  167. Morrison D. A., Sethi G., Sacks J. et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME) // J. Am. Coll. Cardiol. – 2001. – Vol. 38. – P. 143–149.
  168. Morrison D. A., Sethi G., Sacks J. et al. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with postCABG patients // J. Am. Coll. Cardiol. – 2002. – Vol. 40. – P. 1951–1954.
  169. Dougenis D., Brown A. H. Long-term results of reoperations for recurrent angina with internal mammary artery versus saphenous vein grafts // Heart. – 1998. – Vol. 80. – P. 9–13.
  170. Coolong A., Baim D. S., Kuntz R. E. et al. Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients // Circulation. – 2008. – Vol. 117. – P. 790–797.
  171. Baim D. S., Wahr D., George B. et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aortocoronary bypass grafts // Circulation. – 2002. – Vol. 105. – P. 1285–1290.
  172. Seshadri N., Whitlow P. L., Acharya N. et al. Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era // Circulation. – 2002. – Vol. 106. – P. 2346–2350.
  173. Holmes D. R. Jr, Teirstein P., Satler L. et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial // JAMA. – 2006. – Vol. 295. – P. 1264–1273.
  174. Scheller B., Hehrlein C., Bocksch W. et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter // N. Engl. J. Med. – 2006. – Vol. 355. – P. 2113–2124.
  175. Unverdorben M., Vallbracht C., Cremers B. et al. Paclitaxelcoated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis // Circulation. – 2009. – Vol. 119. – P. 2986–2994.
  176. Holzhey D. M., Jacobs S., Mochalski M. et al. Minimally invasive hybrid coronary artery revascularization // Ann. Thorac. Surg. – 2008. – Vol. 86. – P. 1856–1860.
  177. Kon Z. N., Brown E. N., Tran R. et al. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass // J. Thorac. Cardiovasc. Surg. – 2008. – Vol. 135. – P. 367–375.
  178. Mariscalco G., Klersy C., Zanobini M. et al. Atrial fibrillation after isolated coronary surgery affects late survival // Circulation. – 2008. – Vol. 118. – P. 1612–1618.
  179. Ngaage D. L., Schaff H. V., Mullany C. J. et al. Does preoperative atrial fibrillation influence early and late outcomes of coronary artery bypass grafting? // J. Thorac. Cardiovasc. Surg. – 2007. – Vol. 133. – P. 182–189.
  180. Barnett S. D., Ad N. Surgical ablation as treatment for the elimination of atrial fibrillation: a meta-analysis // J. Thorac. Cardiovasc. Surg. – 2006. – Vol. 131. – P. 1029–1035.
  181. Halonen J., Halonen P., Jaђrvinen O. et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial // JAMA. – 2007. – Vol. 297. – P. 1562–1567.
  182. Prasongsukarn K., Abel J. G., Jamieson W. R. et al. The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: a prospective randomized trial // J. Thorac. Cardiovasc. Surg. – 2005. – Vol. 130. – P. 93–98.
  183. Crystal E., Connolly S. J., Sleik K. et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis // Circulation. – 2002. – Vol. 106. – P. 75–80.
  184. Mitchell L. B., Exner D. V., Wyse D. G. et al. Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early after Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial // JAMA. – 2005. – Vol. 294. – P. 3093–3100.
  185. Bradley D., Creswell L. L., Hogue C. W. Jr et al. Pharmacologic prophylaxis: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery // Chest. – 2005. – Vol. 128. – P. 39S–47S.
  186. Burgess D. C., Kilborn M. J., Keech A. C. Interventions for prevention of postoperative atrial fibrillation and its complications after cardiac surgery: a meta-analysis // Eur. Heart J. – 2006. – Vol. 27. – P. 2846–2857.
  187. Lertsburapa K., White C. M., Kluger J. et al. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery // J. Thorac. Cardiovasc. Surg. – 2008. – Vol. 135. – P. 405–411.
  188. Patti G., Chello M., Candura D. et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia after cardiac surgery) study // Circulation. – 2006. – Vol. 114. – P. 1455–1461.
  189. Acikel S., Bozbas H., Gultekin B. et al. Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery // Int. J. Cardiol. – 2008. – Vol. 126. – P. 108–113.
  190. Sanjuan R., Blasco M., Carbonell N. et al. Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery // Ann. Thorac. Surg. – 2004. – Vol. 77. – P. 838–843.
  191. Blomstrom-Lundqvist C., Scheinman M. M., Aliot E. M. et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias–executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society // J. Am. Coll. Cardiol. – 2003. – Vol. 42. – P. 1493–1531.
  192. Peterson E. D., Coombs L. P., DeLong E. R. et al. Procedural volume as a marker of quality for CABG surgery // JAMA. – 2004. – Vol. 291. – P. 195–201.
  193. Djaiani G., Ali M., Borger M. A. et al. Epiaortic scanning modifies planned intraoperative surgical management but not cerebral embolic load during coronary artery bypass surgery // Anesth. Analg. – 2008. – Vol. 106. – P. 1611–1618.
  194. Sabik J. F. III, Blackstone E. H., Gillinov A. M. et al. Influence of patient characteristics and arterial grafts on freedom from coronary reoperation // J. Thorac. Cardiovasc. Surg. – 2006. – Vol. 131. – P. 90–98.
  195. Toumpoulis I. K., Theakos N., Dunning J. Does bilateral internal thoracic artery harvest increase the risk of mediastinitis? // Interact. Cardiovasc. Thorac. Surg. – 2007. – Vol. 6. – P. 787–791.
  196. Sergeant P., Blackstone E., Meyns B. Validation and interdependence with patientvariables of the influence of procedural variables on early and late survival after CABG. K. U. Leuven Coronary Surgery Program // Eur. J. Cardiothorac. Surg. – 1997. – Vol. 12. – P. 1–19.
  197. Sergeant P., Blackstone E., Meyns B. et al. First cardiological or cardiosurgical reintervention for ischemic heart disease after primary coronary artery bypass grafting // Eur. J. Cardiothorac. Surg. – 1998. – Vol. 14. – P. 480–487.
  198. Kieser T. M., Rose S., Kowalewski R., Belenkie I. Transit-time flow predicts outcomes in coronary artery bypass graft patients: a series of 1000 consecutive arterial grafts // Eur. J. Cardiothorac. Surg. – 2010. – Vol. 38. – P. 155–162.
  199. Hannan E. L., Racz M., Holmes D. R. et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era // Circulation. – 2006. – Vol. 113. – P. 2406–2412.
  200. Sixth National Adult Cardiac Surgical Database Report 2008. Dendrite Clinical Systems, Henley-on-Thames, Oxfordshire, UK; 2008.
  201. Sedrakyan A., Wu A. W., Parashar A. et al. Off-pump surgery is associated with reduced occurrence of stroke and other morbidity as compared with traditional coronary artery bypass grafting: a meta-analysis of systematically reviewed trials // Stroke. – 2006. – Vol. 37. – P. 2759–2769.
  202. Shroyer A. L., Grover F. L., Hattler B. et al. On-pump versus off-pump coronary-artery bypass surgery // N. Engl. J. Med. – 2009. – Vol. 361. – P. 1827–1837.
  203. De Luca G., Suryapranata H., Stone G. W. et al. Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials // Am. Heart J. – 2007. – Vol. 153. – P. 343–353.
  204. De Luca G., Dudek D., Sardella G. et al. Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials // Eur. Heart J. – 2008. – Vol. 29. – P. 3002–3010.
  205. Bavry A. A., Kumbhani D. J., Bhatt D. L. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials // Eur. Heart J. – 2008. – Vol. 29. – P. 2989–3001.
  206. Burzotta F., De Vita M., Gu Y. L. et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials // Eur. Heart J. – 2009. – Vol. 30. – P. 2193–2203.
  207. Svilaas T., Vlaar P. J., van der Horst I. C. et al. Thrombus aspiration during primary percutaneous coronary intervention // N. Engl. J. Med. – 2008. – Vol. 358. – P. 557–567.
  208. Vlaar P. J., Svilaas T., van der Horst I. C. et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study // Lancet. – 2008. – Vol. 371. – P. 1915–1920.
  209. Ross A. M., Gibbons R. J., Stone G. W. et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II) // J. Am. Coll. Cardiol. – 2005. – Vol. 45. – P. 1775–1780.
  210. Mehilli J., Dibra A., Kastrati A. et al. Randomized trial of paclitaxeland sirolimus-eluting stents in small coronary vessels // Eur. Heart J. – 2006. – Vol. 27. – P. 260–266.
  211. Buller C. E., Rankin J. M., Carere R. G. et al. Percutaneous coronary intervention in the Occluded Artery Trial: procedural success, hazard, and outcomes over 5 years // Am. Heart J. – 2009. – Vol. 158. – P. 408–415.
  212. Roffi M., Mukherjee D., Chew D. P. et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials // Circulation. – 2002. – Vol. 106. – P. 3063–3067.
  213. Stone G. W., Rogers C., Hermiller J. et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aortocoronary bypass grafts // Circulation. – 2003. – Vol. 108. – P. 548–553.
  214. Mauri L., Cox D., Hermiller J. et al. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial // J. Am. Coll. Cardiol. – 2007. – Vol. 50. – P. 1442–1449.
  215. Daemen J., Simoons M. L., Wijns W. et al. ESC Forum on Drug Eluting Stents European Heart House, Nice, 27–28 September 2007 // Eur. Heart J. – 2009. – Vol. 30. – P. 152–161.
  216. Windecker S., Serruys P. W., Wandel S. et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised noninferiority trial // Lancet. – 2008. – Vol. 372. – P. 1163–1173.
  217. Moses J. W., Leon M. B., Popma J. J. et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery // N. Engl. J. Med. – 2003. – Vol. 349. – P. 1315–1323.
  218. Fajadet J., Wijns W., Laarman G. J. et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial // Circulation. – 2006. – Vol. 114. – P. 798–806.
  219. Gershlick A., Kandzari D. E., Leon M. B. et al. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients // Am. J. Cardiol. – 2007. – Vol. 100. – P. 45M–55M.
  220. Serruys P. W., Silber S., Garg S. et al. Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents // N. Engl. J. Med. – 2010. – Vol. 363. – P. 136–146.
  221. Stone G. W., Ellis S. G., Cox D. A. et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease // N. Engl. J. Med. – 2004. – Vol. 350. – P. 221–231.
  222. Stone G. W., Ellis S. G., Cannon L. et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial // JAMA. – 2005. – Vol. 294. – P. 1215–1223.
  223. Kereiakes D. J., Cannon L. A., Feldman R. L. et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial // J. Am. Coll. Cardiol. – 2010. – Vol. 56. – P. 264–271.
  224. Stone G. W., Midei M., Newman W. et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial // Circulation. – 2009. – Vol. 119. – P. 680–686.
  225. Stone G. W., Rizvi A., Newman W. et al. Everolimus-eluting versus paclitaxeleluting stents in coronary artery disease // N. Engl. J. Med. – 2010. – Vol. 362. – P. 1663–1674.
  226. Ormiston J., Abizaid A., Spertus J. et al. On behalf of the NEVO Res Elution-I investigators. Six months results of the NEVO RES-ELUTION I (NEVO RES-I Trial), a randomized multi-center comparison of the NEVO Sirolimus-Eluting Coronary Stent with the TAXUS Libertee¢ paclitaxel-eluting stent in de novo coronary artery lesions // Circ. Cardiovasc. Interv. – 2010; In press.
  227. Chevalier B., Serruys P. W., Silber S. et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R) paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial // EuroIntervention. – 2007. – Vol. 2. – P. 426–434.
  228. Chevalier B., Silber S., Park S. J. et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial–Phase 2 // Circ. Cardiovasc. Interv. – 2009. – Vol. 2. – P. 188–195.
  229. Mehilli J., Kastrati A., Wessely R. et al. Randomized trial of a nonpolymerbased rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss // Circulation. – 2006. – Vol. 113. – P. 273–279.
  230. Byrne R. A., Kastrati A., Kufner S. et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 LimusEluting Stents (ISAR-TEST-4) trial // Eur. Heart J. – 2009. – Vol. 30. – P. 2441–2449.
  231. Pocock S. J., Lansky A. J., Mehran R. et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials // J. Am. Coll. Cardiol. – 2008. – Vol. 51. – P. 23–32.
  232. Kedhi E., Joesoef K. S., McFadden E. et al. Second-generation everolimuseluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial // Lancet. – 2010. – Vol. 375. – P. 201–209.
  233. Camenzind E., Wijns W., Mauri L. et al. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation // Am. Heart J. – 2009. – Vol. 158. – P. 902–909.
  234. Nordmann A. J., Bucher H., Hengstler P. et al. Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction // Cochrane Database Syst. Rev. – 2005; CD005313.
  235. Kastrati A., Dibra A., Spaulding C. et al. Meta-analysis of randomized trials on drug-eluting stents vs. baremetal stents in patients with acute myocardial infarction // Eur. Heart J. – 2007. – Vol. 28. – P. 2706–2713.
  236. Brilakis E. S., Saeed B., Banerjee S. Drug-eluting stents in saphenous vein graft interventions: a systematic review // EuroIntervention. – 2010. – Vol. 5. – P. 722–730.
  237. Daemen J., Wenaweser P., Tsuchida K. et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study // Lancet. – 2007. – Vol. 369. – P. 667–678.
  238. Cook S., Ladich E., Nakazawa G. et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis // Circulation. – 2009. – Vol. 120. – P. 391–399.
  239. Beijk M. A., Klomp M., Verouden N. J. et al. Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study // Eur. Heart J. – 2010. – Vol. 31. – P. 1055–1064.
  240. Maier L. S., Maack C., Ritter O., Bohm M. Hotline update of clinical trials and registries presented at the German Cardiac Society meeting 2008 (PEPCAD, Lokal-Tax, INH, German ablation registry, German device registry, KTRG.DE registry, DHR, Reality, SWEETHEART registry, ADMA, GERSHWIN) // Clin. Res. Cardiol. – 2008. – Vol. 97. – P. 356–363.
  241. Serruys P. W., Ormiston J. A., Onuma Y. et al. A bioabsorbable everolimuseluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods // Lancet. – 2009. – Vol. 373. – P. 897–910.
  242. Park S. J., Kim Y. H., Park D. W. et al. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis // Circ. Cardiovasc. Interv. – 2009. – Vol. 2. – P. 167–177.
  243. Wu X., Maehara A., Mintz G. S. et al. Virtual histology intravascular ultrasound analysis of non-culprit attenuated plaques detected by grayscale intravascular ultrasound in patients with acute coronary syndromes // Am. J. Cardiol. – 2010. – Vol. 105. – P. 48–53.
  244. Montalescot G., White H. D., Gallo R. et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention // N. Engl. J. Med. – 2006. – Vol. 355. – P. 1006–1017.
  245. Mehta S. R., Bassand J. P., Chrolavicius S. et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 ´ 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy // Am. Heart J. – 2008. – Vol. 156. – P. 1080–1088.
  246. Wiviott S. D., Braunwald E., McCabe C. H. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes // N. Engl. J. Med. – 2007. – Vol. 357. – P. 2001–2015.
  247. Wiviott S. D., Braunwald E., Angiolillo D. J. et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–Thrombolysis in Myocardial Infarction 38 // Circulation. – 2008. – Vol. 118. – P. 1626–1636.
  248. Wallentin L., Becker R. C., Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes // N. Engl. J. Med. – 2009. – Vol. 361. – P. 1045–1057.
  249. Kastrati A., Mehilli J., Neumann F. J. et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial // JAMA. – 2006. – Vol. 295. – P. 1531–1538.
  250. Mehta S. R., Granger C. B., Eikelboom J. W. et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial // J. Am. Coll. Cardiol. – 2007. – Vol. 50. – P. 1742–1751.
  251. Stone G. W., Ware J. H., Bertrand M. E. et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: oneyear results from the ACUITY trial // JAMA. – 2007. – Vol. 298. – P. 2497–2506.
  252. Montalescot G., Wiviott S. D., Braunwald E. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 38): double-blind, randomised controlled trial // Lancet. – 2009. – Vol. 373. – P. 723–731.
  253. Cannon C. P., Harrington R. A., James S. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study // Lancet. – 2010. – Vol. 375. – P. 283–293.
  254. Huber K., Holmes D. R. Jr, van ’t Hof A. W. et al. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial // Eur. Heart J. – 2010. – Vol. 31. – P. 1708–1716.
  255. Stone G. W., Witzenbichler B., Guagliumi G. et al. Bivalirudin during primary PCI in acute myocardial infarction // N. Engl. J. Med. – 2008. – Vol. 358. – P. 2218–2230.
  256. Yusuf S., Mehta S. R., Chrolavicius S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial // JAMA. – 2006. – Vol. 295. – P. 1519–1530.
  257. Lip G. Y., Huber K., Andreotti F. et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary–a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) // Eur. Heart J. – 2010. – Vol. 31. – P. 1311–1318.
  258. O’Donoghue M. L., Braunwald E., Antman E. M. et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a protonpump inhibitor: an analysis of two randomised trials // Lancet. – 2009. – Vol. 374. – P. 989–997.
  259. Akerblom A., James S. K., Koutouzis M. et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) // J. Am. Coll. Cardiol. – 2010. – Vol. 56. – P. 470–475.
  260. Zeymer U., Margenet A., Haude M. et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial // J. Am. Coll. Cardiol. – 2010. – Vol. 56. – P. 463–469.
  261. King S. B. III, Smith S. C. Jr, Hirshfeld J. W. Jr et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, writing on behalf of the 2005 Writing Committee // Circulation. – 2008. – Vol. 117. – P. 261–295.
  262. Piepoli M. F., Corra U., Benzer W. et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation // Eur. J. Cardiovasc. Prev. Rehabil. – 2010. – Vol. 17. – P. 1–17.
  263. Graham I., Atar D., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary // Eur. Heart J. – 2007. – Vol. 28. – P. 2375–2414.
  264. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes // Diabetes Care. – 2009. – Vol. 32. – P. 1327–1334.
  265. Smith S. C. Jr, Allen J., Blair S. N. et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute // J. Am. Coll. Cardiol. – 2006. – Vol. 47. – P. 2130–2139.
  266. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report // Circulation. – 2002. – Vol. 106. – P. 3143–3421.
  267. Cannon C. P., Steinberg B. A., Murphy S. A. et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy // J. Am. Coll. Cardiol. – 2006. – Vol. 48. – P. 438–445.
  268. Duggal J. K., Singh M., Attri N. et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease // J. Cardiovasc. Pharmacol. Ther. – 2010. – Vol. 15. – P. 158–166.
  269. Gibbons R. J., Abrams J., Chatterjee K. et al. ACC/AHA 2002 Guideline Update for the Management of Patients with Chronic Stable Angina–summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina) // Circulation. – 2003. – Vol. 107. – P. 149–158.
  270. Cannon C. P., Braunwald E., McCabe C. H. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes // N. Engl. J. Med. – 2004. – Vol. 350. – P. 1495–1504.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

ЛИТЕРАТУРА
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Оглавление

Данный блок поддерживает скрол*